SCHEMBL6546165

SCHEMBL6546165

C=CCc1cccc(P(=O)(O)O)c1Oc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2B Q14289 3/20 0.38
MAPT P10636 1/20 0.38
NPC1 O15118 2/20 0.38
POLB P06746 2/20 0.38
RAB9A P51151 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
ALPG P10696 1/20 0.36
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KDM4E B2RXH2 3/20 0.34
SRC P12931 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL253410 0.78 POLB (0.44) PTK2BNPC1POLBRAB9AGABRA1
SCHEMBL175552 0.78 GABRA1 (0.46) MAPTRAB9AGLAGAAHTT
SCHEMBL3264284 0.77 FOLH1 (0.41) MAPTPOLBRAB9AGLAGAA
SCHEMBL28577075 0.75 HTT (0.37) MAPTNPC1RAB9AGLAGAA
SCHEMBL10525766 0.75 GABRA1 (0.39) MAPTRAB9AGLAGAAHTT
SCHEMBL27618720 0.75 GABRA1 (0.39) MAPTRAB9AGLAGAAHTT
SCHEMBL2814560 0.74 GABRA1 (0.44) PTK2BMAPTNPC1POLBRAB9A
SCHEMBL11071553 0.74 CTNNB1 (0.41) RAB9AGLAGAAHTTSMN1; SMN2
SCHEMBL774629 0.71 HRH1 (0.44) KDM4EALDH1A1
SCHEMBL10825528 0.71 GABRA1 (0.36) NPC1RAB9AGLAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379533-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS Leo Pharma A/S (DK) 2004-01-14 EP disclosed
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed
WO-2002083696-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS LEO PHARMA A/S (DK) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 PTK2B 3315/4885MAPT 4794/4885NPC1 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.